Search research articles
Contact Us
Filters
Showing results (161-170 of 268) with videos related to
Page
of 27
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
November 1, 1988
The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole)
H F Newman, R Ward, P Workman, et al.
Clinical Genetics
|
January 1, 1974
Total finger ridge count and 45,X mosaicism (with and without Y chromosome)
J M Kerr, L Y Hsu, P Workman, et al.
Anti-Cancer Drug Design
|
October 2, 1998
Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography
E O Aboagye, A B Kelson, M Tracy, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 1, 1989
A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole)
N M Bleehen, H F Newman, T S Maughan, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 1, 1984
A phase I study of the hypoxic cell radiosensitizer Ro-03-8799
J T Roberts, N M Bleehen, P Workman, et al.
Biochemical Pharmacology
|
March 1, 1983
Drug metabolism and chemosensitization. Nitroimidazoles as inhibitors of drug metabolism
P Workman, P R Twentyman, F Y Lee, et al.
American Journal of Primatology
|
October 1, 2019
Baseline cortisol levels and social behavior differ as a function of handedness in marmosets (Callithrix jacchus)
Emma Vaughan, Annie Le, Michaela Casey, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1985
Clinical pharmacokinetics of oral CCNU (lomustine)
F Y Lee, P Workman, J T Roberts, et al.
Carcinogenesis
|
August 1, 1994
Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase
S A Fitzsimmons, A D Lewis, R J Riley, et al.
Biochemical Pharmacology
|
March 9, 1993
Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075)
R J Riley, S A Hemingway, M A Graham, et al.
Page
of 27
Search research articles
Search
Showing results (161-170 of 268) with videos related to
Sort By:
Page
of 27
International Journal of Radiation Oncology, Biology, Physics
|
November 1, 1988
The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole)
H F Newman, R Ward, P Workman, et al.
Clinical Genetics
|
January 1, 1974
Total finger ridge count and 45,X mosaicism (with and without Y chromosome)
J M Kerr, L Y Hsu, P Workman, et al.
Anti-Cancer Drug Design
|
October 2, 1998
Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography
E O Aboagye, A B Kelson, M Tracy, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 1, 1989
A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole)
N M Bleehen, H F Newman, T S Maughan, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 1, 1984
A phase I study of the hypoxic cell radiosensitizer Ro-03-8799
J T Roberts, N M Bleehen, P Workman, et al.
Biochemical Pharmacology
|
March 1, 1983
Drug metabolism and chemosensitization. Nitroimidazoles as inhibitors of drug metabolism
P Workman, P R Twentyman, F Y Lee, et al.
American Journal of Primatology
|
October 1, 2019
Baseline cortisol levels and social behavior differ as a function of handedness in marmosets (Callithrix jacchus)
Emma Vaughan, Annie Le, Michaela Casey, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1985
Clinical pharmacokinetics of oral CCNU (lomustine)
F Y Lee, P Workman, J T Roberts, et al.
Carcinogenesis
|
August 1, 1994
Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase
S A Fitzsimmons, A D Lewis, R J Riley, et al.
Biochemical Pharmacology
|
March 9, 1993
Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075)
R J Riley, S A Hemingway, M A Graham, et al.
Page
of 27